Reveal LINQ™ Insertable Cardiac Monitor
The Reveal LINQ™ insertable cardiac monitor (ICM) with AccuRhythm™ AI algorithms is for patients experiencing infrequent symptoms that require long-term monitoring.
View video
Overview
Accuracy matters
As one of the world's smallest ICMs,1-3 the Reveal LINQ™ ICM works continuously to capture comprehensive and actionable data up to three years.† The device features AccuRhythm™ AI algorithms, which is a groundbreaking platform that applies deep learning artificial intelligence algorithms to Reveal LINQ™ data flowing into the CareLink™ network.
† Reference the Reveal LINQ™ ICM clinician manual for usage parameters.
Product features
Powerfully small and simple
- The Reveal LINQ™ ICM is one-third the size of a AAA battery (1.2 cc).
- It has a minimally invasive, simplified insertion procedure.
- The device is 1.5T and 3T MRI conditional.‡
‡ Reveal LINQ™ has demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal LINQ™ MRI technical manual for more details.
One-third the size of a AAA battery.
AccuRhythm AI algorithms
Experience the difference of Reveal LINQ™ ICM now with AccuRhythm™ AI algorithms for AF and pause.
Reveal LINQ™ ICM,4 the most studied ICM in the market — trusted in over 1 million implants4 is now enhanced with proven AI, providing smarter, more actionable data — without compromise. Preserving over 99.9% true pause and 98.2% true AF alerts relative to Reveal LINQ™ ICM, AccuRhythm™ AI algorithms significantly improve the clinic experience.5
Watch our video to learn more about AccuRhythm™ AI algorithms.
How are AccuRhythm™ AI algorithms applied?
Data workflow
The AccuRhythm™ AI platform applies deep learning AI algorithms to Reveal LINQ™ ICM data flowing into the CareLink™ network to remove false AF and Pause episodes and significantly reduce clinic review burden.5
- Reveal LINQ™
- Data to the cloud
- Medtronic CareLink™ network
- AF and Pause
- AccuRhythm™ AI algorithms
- False events
- True events
Reduce false alerts.
AF and Pause generate ~90% of false alerts in the ICM space.6
The AccuRhythm™ AI algorithms can save clinicians approximately 86 hours of false alert review yearly for every 200 Reveal LINQ™ ICM patients.§,◊,5
85% cumulative reduction in Reveal LINQ™ ICM false alerts.5
§ The validation study performance and time study results were projected onto 104,315 Reveal LINQ™ patients to calculate false alert reduction per year in 200 Reveal LINQ™ ICM patients.
◊ Estimated time savings was calculated based on 11.3 minutes per non-actionable ICM transmission.6
Exclusive services and solutions
1. Streamline device programming and interrogation.
Reveal LINQ™ Mobile Manager
A single, app-based solution for managing:
- Device registration, activation, and CareLink™ pre-enrollment
- Guided workflow animations
- Integrated patient education
2. One of the world’s smallest, most accurate
ICMs.1–3
Reveal LINQ™ ICM
The Reveal LINQ™ ICM is part of the exclusive services and solutions designed to get you back to caring for patients.
3. Direct support for patient monitor connectivity issues.
Medtronic Stay Connected service
A specialized patient service for monitor troubleshooting, connectivity issues, and other questions:
Direct patient line for fast service (866-470-7709)
7 a.m.–7 p.m. CT, Monday–Friday
4. Customize alerts for clinically actionable reports.
CareLink™ network
A remote monitoring network that enables data-driven care decisions:
- CareAlert™ notifications allow for customized reports by clinic and/or individual patient.
- Cardiac Compass™ report provides a 90-day view of patient cardiac data.
Conditionally safe MRI access SureScan™ technology
Reveal LINQ™ ICM is MR-Conditional at 1.5 T and 3.0 T with no post-insertion waiting required.
Reveal LINQ™ insertable cardiac monitor MRI conditions for use
A patient with a Reveal LINQ™ device can be safely scanned in an MR system that meets the following conditions with no post-insertion waiting required. Failure to follow these conditions for use may result in a hazard to the patient during an MRI scan:
- Horizontal cylindrical bore magnet, clinical MRI systems with a static magnetic field of 1.5 Tesla (T) or 3.0 T must be used.
- Hydrogen proton MRI equipment must be used.
- Maximum spatial gradient of the static magnetic field specification must be ≤ 25 T/m (2500 gauss/ cm).
- Whole body gradient systems with gradient slew rate specification must be ≤ 200 T/m/s per axis.
- The Whole Body Specific Absorption Rate (WB-SAR) as reported by the MRI equipment must be ≤ 4.0 W/kg; the head SAR as reported by the MRI equipment must be ≤ 3.2 W/kg.
- Do not use local transmit coils on the chest, trunk, or shoulder region.
- There are no restrictions on the placement of receive-only coils, and there are no restrictions on the use of local transmit or receive coils for imaging of the head or extremities.
Monitoring data
Long-term monitoring for better patient outcomes.
The Reveal LINQ™ ICM continuously monitors patients for up to three years.† Learn more about long-term heart monitoring for suspected AF, syncope, and cryptogenic stroke.
Benefits of continuous monitoring and automatic arrhythmia detection with ICMs
|
|
30 days is not enough |
2 years is not enough |
Superior diagnostic yield |
Informed treatment decisions |
|---|---|---|---|---|
| Cryptogenic stroke |
88% of patients who had AF would have been missed if only monitored for 30 days#,7 |
17.6% of cryptogenic stroke AF diagnoses occur after monitoring with an ICM for 1 and 3 years7 |
8.8x more AF detected at 36 months with ICM vs. conventional follow-upΔ,7 |
97% of patients in whom AF was detected received oral anticoagulants at 12 months7 |
| Syncope |
74% of syncope diagnoses would have been missed if using a 30-day monitor strategy#,8 |
20% of syncope diagnoses occur between years 2 and 39 |
3.6x more likely to reach a syncope diagnosis with ICM vs. conventional care∞,10 |
82% of Reveal™ ICM guided diagnoses led to treatment11 |
| High-risk for AF (REVEAL AF study)†† |
84.5% of patients with AF would have been missed if only monitored for 30 days12 |
16% of patients with ICM-detected AF would have been missed if monitoring stopped at 2 years12 |
4.3x more likely to reach a diagnosis with ICM in 12 months vs. one-time, 30-day monitor13 |
76% of patients with ICM-detected AF had a change in clinical management12 |
† Reference the Reveal LINQ™ ICM clinician manual for usage parameters.
‡ Reveal LINQ™ has demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal LINQ™ MRI technical manual for more details.
§ The validation study performance and time study results were projected onto 104,315 Reveal LINQ™ patients to calculate false alert reduction per year in 200 Reveal LINQ™ ICM patients.
◊ Estimated time savings was calculated based on 11.3 minutes per non-actionable ICM transmission.6
¶ The CRYSTAL-AF Study was a randomized, controlled study conducted on 441 patients to assess whether long-term monitoring with Reveal™ XT is more effective than conventional follow-up (control) for detecting atrial fibrillation in patients with cryptogenic stroke.
#Based on Kaplan-Meier estimates.
Δ In the CRYSTAL-AF study, the control group included 88 conventional ECGs, 20 24-hour Holters, and 1 event recorder.
∞ 2018 ESC Guidelines for Diagnosis and Management of Syncope defined conventional testing as undefined physician discretion for monitoring excluding ICM, External Loop Recorder, Tilt Test, EP Study, Recurrent 12-lead ECG, or 7-day Holter monitor.
†† The REVEAL AF Study was a prospective, single-arm, multicenter study to quantify the incidence of AF in patients at high risk for but without previously known AF using an ICM (Reveal LINQ™ or Reveal™ XT).
1. Reveal LINQ™ insertable cardiac monitor clinician manual.
2. Assert-IQ™ Model DM5000, DM5300, DM5500, insertable cardiac monitor manual. 2023.
3. ICM accuracy comparison guide. Medtronic data on file. 2021.
4. Medtronic Reveal™ ICM family data. Data on file. 2024.
5. Radtke A, Hall M. AccuRhythm™ AI AF & pause algorithms [white paper]. April 2023. Medtronic data on file.
6. O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote monitoring of implantable loop recorders: false-positive alert episode burden. Circ Arrhythm Electrophysiol. 2021;14(11):e009635. doi: 10.1161/CIRCEP.121.009635.
7. Sanna T, Diener H-C, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–2486. doi: 10.1056/NEJMoa1313600.
8. Rogers J, et al. Abstract 272: Sensitivity of conventional monitoring strategies to diagnose patients with pause arrhythmias relative to insertable cardiac monitors. 2020 AHA QCOR Abstract.
9. Furukawa T, Maggi R, Bertolone C, Fontana D, Brignole M. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope. J Cardiovasc Electrophysiol. 2012;23(1):67–71. doi: 10.1111/j.1540-8167.2011.02133.x.
10. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883–1948. doi: 10.1093/eurheartj/ehy037.
11. Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. 2011;13(2):262–269. doi: 10.1093/europace/euq418.
12. Reiffel JA, Verma A, Kowey PR, et al. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: The REVEAL AF study. JAMA Cardiol. 2017;2(10):1120–1127. doi: 10.1001/jamacardio.2017.3180.
13. Reiffel JA, Verma A, Kowey PR, et al. Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. Am Heart J. 2020;219:128–136. doi: 10.1016/j.ahj.2019.07.016.